Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2014 Mar 10;32(12):1394-7. doi: 10.1016/j.vaccine.2013.11.106. Epub 2014 Jan 30.

Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome.

Author information

1
1st Department of Pediatrics, Infectious Diseases Unit, "Aghia Sophia" Children's Hospital, Athens University School of Medicine, Athens, Greece. Electronic address: chrisliakou_med@hotmail.com.
2
Department of Nephrology, "P. and A. Kyriakou" Children's Hospital, Athens, Greece.
3
1st Department of Pediatrics, Infectious Diseases Unit, "Aghia Sophia" Children's Hospital, Athens University School of Medicine, Athens, Greece.

Abstract

Safety and immunogenicity of a booster dose of 7-valent pneumococcal conjugate vaccine (PCV7) were evaluated in 29 patients with idiopathic nephrotic syndrome (INS), who had been primed 12 months earlier with one dose of PCV7. PCV7 was not associated with increased risk of INS relapse (RR=0.77, p=0.8) and serotype-specific antibodies increased in all subjects at 1 month (p<0.01). The quantitative characteristics of immune response and the effect of treatment with mycophenolate mofetil and/or cyclosporine A following booster PCV7 were similar with primary response. Additional PCV7 doses could be safely given in children with INS to increase circulating antibodies above the protective threshold.

KEYWORDS:

Booster vaccination; Idiopathic nephrotic syndrome; Pneumococcal conjugate vaccine; Safety

PMID:
24486348
DOI:
10.1016/j.vaccine.2013.11.106
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center